6-羟基-2-甲基喹啉-4-羧酸 | 50741-53-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-羟基-2-甲基喹啉-4-羧酸
• 中文别名: 6-羟基-2-甲基喹啉-4-羧基酸
• 英文名称: 6-hydroxy-2-methyl-quinoline-4-carboxylic acid
• 英文别名: 6-Hydroxy-2-methyl-chinolin-4-carbonsaeure；6-Hydroxy-2-methylquinoline-4-carboxylic acid
• CAS: 50741-53-2
• 化学式: C₁₁H₉NO₃
• 分子量: 203.197
• InChiKey: ZMFWTUBNIJBJDB-UHFFFAOYSA-N

物化性质

• 熔点：
  >340 °C
• 沸点：
  414.7±40.0 °C(Predicted)
• 密度：
  1.410±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  70.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-羟基-2-甲基喹啉-4-羧酸 在 重氮甲烷 作用下， 生成 methyl 6-methoxy-2-methylquinoline-4-carboxylate
  参考文献：
  名称：

  Dane et al., Justus Liebigs Annalen der Chemie, 1957, vol. 607, p. 92,101

  摘要：

  DOI：
• 作为产物：
  描述：

  6-甲氧基-2-甲基-喹啉-4-羧酸 在 盐酸 作用下， 生成 6-羟基-2-甲基喹啉-4-羧酸
  参考文献：
  名称：

  Halberkann, Chemische Berichte, 1921, vol. 54, p. 3096

  摘要：

  DOI：

文献信息

• Nicotinamide derivatives useful as pde4 inhibitors
  申请人：Barber Gordon Christopher

  公开号：US20060178408A1

  公开（公告）日：2006-08-10

  This invention relates to nicotinamide derivatives of general formula (I): in which R 1 , Z and R 2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

  本发明涉及通式（I）的烟酰胺衍生物，其中R1，Z和R2具有在此定义的含义，并涉及用于制备、制备中间体、含有和使用这种衍生物的组合物的过程。
• Compounds
  申请人：Barber Gordon Christopher

  公开号：US20050043326A1

  公开（公告）日：2005-02-24

  This invention relates to nicotinamide derivatives of general formula (I): in which R 1 , Z and R 2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

  本发明涉及一般式(I)的烟酰胺衍生物，其中R1、Z和R2具有本文中定义的含义，以及制备、制备中间体、含有和使用这些衍生物的组合物的过程。
• Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)
  作者：Matthäus Getlik、David Smil、Carlos Zepeda-Velázquez、Yuri Bolshan、Gennady Poda、Hong Wu、Aiping Dong、Ekaterina Kuznetsova、Richard Marcellus、Guillermo Senisterra、Ludmila Dombrovski、Taraneh Hajian、Taira Kiyota、Matthieu Schapira、Cheryl H. Arrowsmith、Peter J. Brown、Masoud Vedadi、Rima Al-awar

  DOI：10.1021/acs.jmedchem.5b01630

  日期：2016.3.24

  WD repeat-containing protein 5 (WDR5) is an important component of the multiprotein complex essential for activating mixed-lineage leukemia 1 (MLL1). Rearrangement of the MLL1 gene is associated with onset and progression of acute myeloid and lymphoblastic leukemias, and targeting the WDR5-MLL1 interaction may result in new cancer therapeutics. Our previous work showed that binding of small molecule ligands to WDR5 can modulate its interaction with MLL1, suppressing MLL1 methyltransferase activity. Initial structure activity relationship studies identified N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides as potent and selective antagonists of this protein protein interaction. Guided by crystal structure data and supported by in silico library design, we optimized the scaffold by varying the C-1 benzamide and C-S substituents. This allowed us to develop the first highly potent (K-disp < 100 nM) small molecule antagonists of the WDR5-MLL1 interaction and demonstrate that N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide 16d (OICR-9429) is a potent and selective chemical probe suitable to help dissect the biological role of WDR5.
• v. Euler et al., Arkiv foer Kemi, 1953, vol. 5, p. 251,252
  作者：v. Euler et al.

  DOI：——

  日期：——
• LOW AFFINITY SCREENING METHOD
  申请人：Graffinity Pharmaceuticals Aktiengesellschaft

  公开号：EP1360489A1

  公开（公告）日：2003-11-12